Navigation Links
Terumo Heart Reports Summary of DuraHeart(TM) LVAS Clinical Trial Results
Date:9/17/2007

ANN ARBOR, Mich., Sept. 17 /PRNewswire/ -- Terumo Heart, Inc. announced today that it had a successful European Launch Symposium at the European Association of Cardio-Thoracic Surgeons (EACTS) meeting in Geneva, Switzerland.

(Logo: http://www.newscom.com/cgi-bin/prnh/20061027/DEF004LOGO )

(Logo: http://www.newscom.com/cgi-bin/prnh/20070227/CLTU043LOGO )

A summary of the European Clinical Trial results for the DuraHeart(TM) Left Ventricular Assist System (LVAS) was presented by Dr. Aly El-Banayosy from the Heart Center Nordrhein-Westfalen in Bad Oeynhausen, Germany, followed by the presentation "The Emerging New Era of Mechanical Circulatory Support," by Dr. Eric Rose of Columbia University Medical Center in New York.

The symposium highlighted the DuraHeart device, as well as the BioValsalva Aortic Valved Conduit developed by Vascutek Ltd, a Terumo Company.

A summary of DuraHeart LVAS clinical results to-date (as of September 15, 2007):

* Patients enrolled = 33

* Median age (years) = 57 (29-73)

* Mean support duration (days) = 231194 (range: 17-803)

* Cumulative support duration = 7610 days (> 20 years)

* 7 patients (21%) supported > 1 year, and one supported > 2 years.

* 12 patients (36%) remain on support with a mean duration > 1 year (375

196 days)

* Kaplan Meier survival at 1 and 2 years was: 77% (all patients), 80% (<65

yrs), 90% (<60 yrs) and 100% (<50)

Chisato Nojiri, M.D., Ph.D., Chief Executive Officer for Terumo Heart, Inc., said; "We have had a number of significant milestones this year, most importantly receiving the CE Mark and a successful commercial launch in Europe."

The interest from surgeons at the EACTS has been extremely good. Dr. Nojiri commented, "We have been very pleased w
'/>"/>

SOURCE Terumo Heart, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
2. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
3. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
4. Treating Heart Disease Risk Factors May Slow Alzheimers Disease Progression
5. Pilot Phase 3 Results of NovaCardias KW-3902 for Acute Congestive Heart Failure Presented at Late-Breaking Session of Heart Failure Congress 2007
6. Drug for Treatment of Heart Failure Does Not Improve Survival, Compared to More Widely-used Medication
7. deCODE Announces Positive Topline Results for Phase I Study of DG051 for the Prevention of Heart Attack
8. Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study
9. Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study
10. First Controlled Large-Scale Intervention Angiotensin Receptor Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study Demonstrates Significant Reduction in Blood Pressure and Protection of Organs with Valsartan
11. New Anti-Rejection Medication 6-Month Results for Heart Transplant Recipients to Be Released at International Heart and Lung Transplant Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2008)...- Bayer together with Nektar Therapeutics present ... treatment of pneumonia in intubated and ...TO and BERLIN, May 19 /- Ba...Nasdaq: NKTR ), today presented positive,prelimin...ination Amikacin,Inhale at the American Thoracic S...
(Date:5/19/2008)... - RDEA594 Data to Be Presented at the 2008 Annu... the European League Against Rheumatism (EULAR) -,...lanned in Second Half of ...tCall/ -- Ardea Biosciences, Inc.,(Nasdaq: RDEA )...velopment,candidate for the treatment of patients ...
(Date:5/19/2008)... MARSEILLE, France, May 19 /- IPSO...r that develops and markets molecular diagnostic,a...that researchers from,the University of Texas MD A...esent the results of two studies on the Genomic Gr...n Chicago from May 30 to June 3, 2008. The data,in...
(Date:5/18/2008)... -- Additional Data Demonstrated Higher Overall...and Symptom Relief versus Placebo --, SAN DIEGO, ... Inc.,today reported results from three pivotal Ph...TAK-390MR, the first proton pump inhibitor (PPI),w... in healing patients,with erosive esophagitis (EE)...
Breaking Medicine Technology:Amikacin Inhale Shows Promising Results in Phase II Study 2Amikacin Inhale Shows Promising Results in Phase II Study 3Amikacin Inhale Shows Promising Results in Phase II Study 4Amikacin Inhale Shows Promising Results in Phase II Study 5Amikacin Inhale Shows Promising Results in Phase II Study 6Amikacin Inhale Shows Promising Results in Phase II Study 7Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594 2Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594 3Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594 4Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594 5Ipsogen Announces Three Studies at the American Society of Clinical Oncology (ASCO) Meeting Extending the Utility of the Genomic Grade Index for Predicting Response to Chemotherapy in Breast Cancer 2Ipsogen Announces Three Studies at the American Society of Clinical Oncology (ASCO) Meeting Extending the Utility of the Genomic Grade Index for Predicting Response to Chemotherapy in Breast Cancer 3Ipsogen Announces Three Studies at the American Society of Clinical Oncology (ASCO) Meeting Extending the Utility of the Genomic Grade Index for Predicting Response to Chemotherapy in Breast Cancer 4TAP Pharmaceutical Products Inc. Announces Phase 3 TAK-390MR Data Demonstrating Higher Overall Healing Versus Lansoprazole in Patients with Erosive Esophagitis 2TAP Pharmaceutical Products Inc. Announces Phase 3 TAK-390MR Data Demonstrating Higher Overall Healing Versus Lansoprazole in Patients with Erosive Esophagitis 3TAP Pharmaceutical Products Inc. Announces Phase 3 TAK-390MR Data Demonstrating Higher Overall Healing Versus Lansoprazole in Patients with Erosive Esophagitis 4Isis Pharmaceuticals and Thomas McNerney 26 Partners Announce That the Newly Formed Altair Therapeutics Will Develop Antisense Drugs for Respiratory 1281 1Isis Pharmaceuticals and Thomas McNerney 26 Partners Announce That the Newly Formed Altair Therapeutics Will Develop Antisense Drugs for Respiratory 1281 2Isis Pharmaceuticals and Thomas McNerney 26 Partners Announce That the Newly Formed Altair Therapeutics Will Develop Antisense Drugs for Respiratory 1281 3Isis Pharmaceuticals and Thomas McNerney 26 Partners Announce That the Newly Formed Altair Therapeutics Will Develop Antisense Drugs for Respiratory 1281 4Isis Pharmaceuticals and Thomas McNerney 26 Partners Announce That the Newly Formed Altair Therapeutics Will Develop Antisense Drugs for Respiratory 1281 5Rigel to Present Research Programs at Scientific Conferences 1279 1Rigel to Present Research Programs at Scientific Conferences 1279 2Rigel to Present Research Programs at Scientific Conferences 1279 3Targeted Nanoparticles Offer Promise in the Battle Against Cancer 529 1Targeted Nanoparticles Offer Promise in the Battle Against Cancer 529 2Why Healthy People Should Consider Individual Disability Insurance 3762 1Why Healthy People Should Consider Individual Disability Insurance 3762 2
(Date:5/20/2008)...elevised skin health program, the first of its kin... issues affecting an increasingly diverse,America,...ay, May 24, 2008., SAN FRANCISCO, May 20 /PRNewsw...ial designed to educate and inform the public abou...the Women,s Dermatologic Society (WDS),is pleased ...
(Date:5/20/2008)...ELMSFORD, Mass., May 20 /PRNewswire-FirstCall/ -- ... leading provider of specialized,high-performance...d signal,processing applications, announced that m...s business on Thursday, May 29, 2008 at the Cowen ...nce. The Conference will be,held at the New York P...
(Date:5/20/2008)...archers at the Peninsula Medical School in the Sou... San Raffaele Scientific Institute in Milan and Ca...ed a protein that is key to the regeneration of da...uld with further research lead to understanding di...de clues to methods of repairing damage in the cen...
(Date:5/20/2008)...ur years of paperless prescription use yields prac... health plans and policy makers, WASHINGTON, MAY ...th,Initiative (eHI) and the Center for Improving M...ate of a widely anticipated report detailing the,i... on physicians,consumers, employers, health plans...
Breaking Medicine News(10 mins):Health News:Women's Dermatologic Society Announces Collaboration on 'America's Ethnic Skin: An Al Roker Health Special' 2Health News:Women's Dermatologic Society Announces Collaboration on 'America's Ethnic Skin: An Al Roker Health Special' 3Health News:Mercury Computer Systems to Present at the Cowen and Company 20/20 Technology-Media-Telecom Conference on May 29, 2008 2Health News:Protein key to neuro-regeneration 2Health News:eHealth Initiative and the Center for Improving Medication Management to Present Report Detailing Both Impact of E-Prescriptions on U.S. Health Care System and Guidelines for Achieving Optimal Results 2Health News:eHealth Initiative and the Center for Improving Medication Management to Present Report Detailing Both Impact of E-Prescriptions on U.S. Health Care System and Guidelines for Achieving Optimal Results 3
... to explore the relationship between bicycle ridin...phasized whether or not a causal relationship exis... erectile dysfunction (disease). // However, it is...on according to Dr. Schrader, an expert in the fie...
...ata, not even sparing the city's upscale neighbour...ee has admitted that the fever that swept through ...fever. There have been reports of 4 casualties and...e of dengue in eight other people. The unofficial ...
... continues to daily kill a few more people in Utta...ring areas like Nepal. In this special report we r...ain fever and provide some essential information o... its life cycle and prevention. The first histo...
...mising with the life of its patients and selling e...ispensary says a latest report. The criminal opera...h exposed and captured unethical conduct on camera...those involved first went into denial mode immedia...
Other Medicine News:Health News:Brain Fever or Encephalitis Spreading in North India 2
...e beyond your investment., ,The Centiva/5 Critica...d time demands of the critical care environment. T... mind combining a compact size with high levels of...uable space around the patients bed and allows you...
...ther treatments for ,ED (e.g. Viagra, Injections...,Vacuum Therapy is gaining increasing ,popul...of the very positive associated benefits. ,In fa...ercise to prevent atrophy and to promote penile he...
...Mesh LP Self-Forming Plug is combining a lightweig... This results in a very soft hernia plug which sta...rd Plugs less foreign body material is included in... hernia size and shape allows for a softer and les...
...Mesh Self-Forming Plug is a mesh plug to treat lar...l hernias and femoralhernias. The self-expanding p...mpletely. Premilene Mesh Self-Forming Plug is a pr...h. The plug corresponds with all properties of Pre...
Medicine Products: